Advertisement
Screener

OUTLOOK THERAPEUTICS, INC. (OTLK) Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate

2.4 / 5 stars · 34/70 Roast Me

OUTLOOK THERAPEUTICS, INC. Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate

OUTLOOK THERAPEUTICS, INC. (OTLK) reported Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate of 0.00% for the 12-month period ending 2019-09-30, per its 10-K filed 2019-12-19.

Discontinued › Notes › Share-Based Payment Arrangement, Disclosure › Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions and Methodology

us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate · last filed 2019-12-19

  • OUTLOOK THERAPEUTICS, INC. share-based compensation arrangement by share-based payment award, fair value assumptions, expected dividend rate for the quarter ending 2018-12-31 was 0.00%.
  • OUTLOOK THERAPEUTICS, INC. share-based compensation arrangement by share-based payment award, fair value assumptions, expected dividend rate for the quarter ending 2017-12-31 was 0.00%.
  • OUTLOOK THERAPEUTICS, INC. share-based compensation arrangement by share-based payment award, fair value assumptions, expected dividend rate for fiscal 2019 was 0.00%.
  • OUTLOOK THERAPEUTICS, INC. share-based compensation arrangement by share-based payment award, fair value assumptions, expected dividend rate for fiscal 2018 was 0.00%.
Period endShare-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate 3 monthShare-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate 6 monthShare-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate 9 monthShare-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate 12 month
2019-09-300.00%
10-K · filed 2019-12-19
2019-06-300.00%
10-Q · filed 2019-08-14
2019-03-310.00%
10-Q · filed 2019-05-15
2018-12-310.00%
10-Q · filed 2019-02-14
2018-09-300.00%
10-K · filed 2019-12-19
2018-06-300.00%
10-Q · filed 2019-08-14
2018-03-310.00%
10-Q · filed 2019-05-15
2017-12-310.00%
10-Q · filed 2018-02-14

Similar stocks

Stock NameCountryMarket CapPE Ratio
Acumen Pharmaceuticals, Inc. (ABOS)United States$0.162B-1.83
Humacyte, Inc. (HUMA)United States$0.155B-2.26
Voyager Therapeutics, Inc. (VYGR)United States$0.173B-1.99
PRECISION BIOSCIENCES INC (DTIL)United States$0.175B-3.95
Coherus Oncology, Inc. (CHRS)United States$0.182B-1.63
Tenaya Therapeutics, Inc. (TNYA)United States$0.140B-1.60
Alpha Cognition Inc. (ACOG)$0.185B-6.77
Caribou Biosciences, Inc. (CRBU)United States$0.134B-1.79
Armata Pharmaceuticals, Inc. (ARMP)United States$0.132B
Neumora Therapeutics, Inc. (NMRA)United States$0.132B-1.48